Screening for latent TB in patients with inflammatory arthritis who will be starting TNFα inhibitors is important to prevent complications of TB-reactivation. However, currently there is no ‘gold standard’ for the diagnosis of latent TB.
Approval for golimumab (which will by marketed under the trade name Simponi) was granted this week by the U.S. Food and Drug Administration. The drug received approval for the treatment of moderate to severe RA (in conjunction with methotrexate), active psoriatic arthritis (as monotherapy or with methotrexate), and active ankylosing spondylitis at a dose of [...]
There are currently no biologic treatment options available for patients with psoriatic arthritis (PsA) who are non-responsive to traditional non-biologic DMARDs and TNF inhibitors. Interleukins (IL) 12 and 23 have been implicated in the pathogenesis of plaque psoriasis. A humanized monoclonal antibody directed against these cytokines, ustekinumab, has demonstrated efficacy in the treatment of psoriasis [...]
The T-cell inhibitor efalizumab (Raptiva) has demonstrated efficacy in the treatment of moderate to severe plaque psoriasis. However, it has not demonstrated efficacy for the treatment of psoriatic arthritis and, in one study, was associated with worsening of arthritis symptoms. Only a minority of individuals with psoriasis have a concomitant inflammatory arthritis, making therapy with efalizumab an option for the treatment of a large number of psoriasis patients who have no articular involvement.